Published in Eukaryot Cell on November 17, 2006
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol (2009) 1.43
Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell (2007) 1.39
Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell (2007) 1.36
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A (2009) 1.19
Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest (2010) 1.16
Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan. Eukaryot Cell (2008) 1.13
Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol (2011) 1.01
The interaction between Candida krusei and murine macrophages results in multiple outcomes, including intracellular survival and escape from killing. Infect Immun (2011) 0.98
Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans. Front Microbiol (2011) 0.98
Chronological aging is associated with biophysical and chemical changes in the capsule of Cryptococcus neoformans. Infect Immun (2011) 0.87
Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans. J Phys Chem B (2008) 0.85
In good company: association between fungal glycans generates molecular complexes with unique functions. Front Microbiol (2012) 0.85
A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan. Fungal Genet Biol (2012) 0.81
Capsule growth in Cryptococcus neoformans is coordinated with cell cycle progression. MBio (2014) 0.81
Variability of phenotypic traits in Cryptococcus varieties and species and the resulting implications for pathogenesis. Future Microbiol (2010) 0.78
Temporal behavior of capsule enlargement by Cryptococcus neoformans. Eukaryot Cell (2013) 0.77
Effects of radiation type and delivery mode on a radioresistant eukaryote Cryptococcus neoformans. Nucl Med Biol (2015) 0.75
A colorimetric method for the determination of sugars. Nature (1951) 8.76
Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun (1986) 4.91
Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun (1972) 4.45
Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol (1980) 4.28
Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol (1994) 4.22
Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods (1984) 4.15
Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J Clin Invest (1985) 3.98
The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol (1982) 3.92
The extracellualr polysaccharides of bacteria. Bacteriol Rev (1958) 3.59
Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun (1994) 3.46
Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol Cell Biol (2001) 3.11
In vitro phagocytosis and intracellular fate of variously encapsulated strains of Cryptococcus neoformans. Infect Immun (1972) 3.05
Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods (1992) 2.97
A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot Cell (2003) 2.59
Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials (1988) 2.32
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem (2005) 2.07
Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis (1993) 2.03
Cell wall alpha-1,3-glucan is required to anchor the Cryptococcus neoformans capsule. Mol Microbiol (2003) 2.00
Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3. Infect Immun (1988) 1.94
Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect Immun (1977) 1.93
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
How does Cryptococcus get its coat? Trends Microbiol (2000) 1.86
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol (2005) 1.80
'Ready made' virulence and 'dual use' virulence factors in pathogenic environmental fungi--the Cryptococcus neoformans paradigm. Curr Opin Microbiol (2003) 1.79
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun (1996) 1.71
Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun (1997) 1.69
Cryptococcus neoformans of unusual morphology. Appl Microbiol (1973) 1.67
Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol (2004) 1.66
Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun (1998) 1.63
Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell (2005) 1.58
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis (2006) 1.47
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol (2002) 1.45
The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol (2006) 1.37
The capsular dynamics of Cryptococcus neoformans. Trends Microbiol (2006) 1.35
Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by 13C NMR spectroscopy. Carbohydr Res (1992) 1.34
Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun (2004) 1.31
Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect Immun (1995) 1.31
Characterization of protein and mannan polysaccharide antigens of yeasts, moulds, and actinomycetes. Curr Top Med Mycol (1985) 1.30
Spatial and temporal sequence of capsule construction in Cryptococcus neoformans. Mol Microbiol (2001) 1.29
Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun (2003) 1.27
Estimating the relative contributions of virulence factors for pathogenic microbes. Infect Immun (2006) 1.21
Large Cryptococcus neoformans isolated from brain abscess. J Clin Microbiol (1985) 1.19
Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect Immun (1998) 1.16
Capsule and melanin synthesis in Cryptococcus neoformans. Med Mycol (2001) 1.11
Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy. Carbohydr Res (1996) 1.07
The electrophoretic mobility of micro-organisms. Adv Microb Physiol (1973) 1.03
Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release. Med Mycol (1999) 1.03
The volume and hydration of the Cryptococcus neoformans polysaccharide capsule. Fungal Genet Biol (2006) 1.01
Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun (2004) 0.98
Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans. J Immunol (2004) 0.96
Structure of the 13C-enriched O-deacetylated glucuronoxylomannan of Cryptococcus neoformans serotype A determined by NMR spectroscopy. Carbohydr Res (1997) 0.95
Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Cell Microbiol (2006) 0.95
Studies on capsule synthesis of Cryptococcus neoformans. Sabouraudia (1965) 0.94
The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies. Curr Mol Med (2005) 0.93
Biological and electron microscopic changes in gamma radiated Cryptococcus neoformans. Mycopathol Mycol Appl (1972) 0.93
Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells. Infect Immun (1996) 0.89
Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype C as determined by 2D 1H NMR spectroscopy. Carbohydr Res (1995) 0.88
Equatorial ring-like channels in the Cryptococcus neoformans polysaccharide capsule. FEMS Yeast Res (2006) 0.87
The phagocytosis and transforming activity of crystalline metal sulfide particles are related to their negative surface charge. Carcinogenesis (1982) 0.87
Immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum. J Clin Microbiol (2004) 0.85
Fenton-dependent damage to carbohydrates: free radical scavenging activity of some simple sugars. J Agric Food Chem (2003) 0.83
[Radiochemistry of polysaccharides (review)]. Radiats Biol Radioecol (1999) 0.83
Misconduct accounts for the majority of retracted scientific publications. Proc Natl Acad Sci U S A (2012) 5.89
Causes for the persistence of impact factor mania. MBio (2014) 3.77
Why has the number of scientific retractions increased? PLoS One (2013) 3.59
Retracted science and the retraction index. Infect Immun (2011) 3.35
The contribution of melanin to microbial pathogenesis. Cell Microbiol (2003) 3.12
Cryptococcosis. Infect Dis Clin North Am (2002) 3.01
Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr Biol (2006) 2.92
Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A (2002) 2.68
Passive antibody therapy for infectious diseases. Nat Rev Microbiol (2004) 2.64
Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot Cell (2006) 2.55
Public health and biosecurity. Adaptations of avian flu virus are a cause for concern. Science (2012) 2.52
Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell (2007) 2.42
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
NIH peer review reform--change we need, or lipstick on a pig? Infect Immun (2009) 2.21
Impact of melanin on microbial virulence and clinical resistance to antimicrobial compounds. Antimicrob Agents Chemother (2006) 2.12
The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem (2005) 2.07
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res (2004) 2.00
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
Reforming science: methodological and cultural reforms. Infect Immun (2011) 1.85
The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect (2003) 1.84
CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity (2002) 1.83
More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol (2003) 1.81
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest (2011) 1.80
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.76
Vesicular transport in Histoplasma capsulatum: an effective mechanism for trans-cell wall transfer of proteins and lipids in ascomycetes. Cell Microbiol (2008) 1.73
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A (2003) 1.71
Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. PLoS One (2007) 1.70
Lost in translation--basic science in the era of translational research. Infect Immun (2009) 1.70
The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen. J Biol Chem (2007) 1.67
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
The presence of female conveners correlates with a higher proportion of female speakers at scientific symposia. MBio (2014) 1.63
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc Natl Acad Sci U S A (2010) 1.62
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol (2005) 1.61
Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest (2003) 1.60
Important science--it's all about the SPIN. Infect Immun (2009) 1.59
A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med (2010) 1.58
Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin. Curr Opin Microbiol (2008) 1.58
Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother (2002) 1.57
Global warming will bring new fungal diseases for mammals. MBio (2010) 1.56
Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med (2004) 1.56
Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog (2007) 1.55
Policy: Adaptations of avian flu virus are a cause for concern. Nature (2012) 1.54
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Vertebrate endothermy restricts most fungi as potential pathogens. J Infect Dis (2009) 1.51
Cell-to-cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages. BMC Immunol (2007) 1.51
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med (2004) 1.47
Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J Infect Dis (2006) 1.47
Monoclonal antibody-based therapies for microbial diseases. Vaccine (2009) 1.47
Sec6-dependent sorting of fungal extracellular exosomes and laccase of Cryptococcus neoformans. Mol Microbiol (2008) 1.46
Synthesis and assembly of fungal melanin. Appl Microbiol Biotechnol (2011) 1.45
The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol (2003) 1.45
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
Cryptococcus neoformans virulence is enhanced after growth in the genetically malleable host Dictyostelium discoideum. Infect Immun (2003) 1.44
The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence (2011) 1.42
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother (2006) 1.42
Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun (2005) 1.42
Microstructure of cell wall-associated melanin in the human pathogenic fungus Cryptococcus neoformans. Biochemistry (2005) 1.40
Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun (2010) 1.40
Experimental murine cryptococcal infection results in contamination of bedding with Cryptococcus neoformans. Contemp Top Lab Anim Sci (2003) 1.40
Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell (2007) 1.39
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med (2006) 1.38
A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun (2006) 1.38
The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol (2006) 1.37
Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol (2008) 1.36
Binding of the wheat germ lectin to Cryptococcus neoformans suggests an association of chitinlike structures with yeast budding and capsular glucuronoxylomannan. Eukaryot Cell (2007) 1.36
The radioprotective properties of fungal melanin are a function of its chemical composition, stable radical presence and spatial arrangement. Pigment Cell Melanoma Res (2008) 1.36
Reforming science: structural reforms. Infect Immun (2011) 1.36
The capsular dynamics of Cryptococcus neoformans. Trends Microbiol (2006) 1.35
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol (2008) 1.32
Histoplasma capsulatum synthesizes melanin-like pigments in vitro and during mammalian infection. Infect Immun (2002) 1.31
Vesicle-associated melanization in Cryptococcus neoformans. Microbiology (2009) 1.31
Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J Immunol (2002) 1.30
The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun (2007) 1.30
Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol (2003) 1.30
Mechanistic science. Infect Immun (2009) 1.29
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe (2013) 1.26
Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A (2004) 1.26
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun (2002) 1.24
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol (2002) 1.24
Characterization of yeast extracellular vesicles: evidence for the participation of different pathways of cellular traffic in vesicle biogenesis. PLoS One (2010) 1.24
Males are overrepresented among life science researchers committing scientific misconduct. MBio (2013) 1.22
Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol (2006) 1.22